From £7.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £7.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Edison: when is your follow up to the worst research note ever ( Buy Slater & Gordon) due?

By Tom Winnifrith | Saturday 16 April 2016


Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


I am not 100% up to speed on the comings and goings at paid researcher Edison so am unaware if its star analyst The Right Hon Charlie Gibson is still on a police curfew and wearing an electronic ankle bracelet after his spot of bother trying to give a member of the working classes, who happened to be a rozzer, a damn good thrashing. On the subject of convicts (well at least those descended from them) and damn good thrashings I note that shares in Aussie law firm Slater & Gordon (SGH) are now 28 Aussie cents having been A$2.67 on 23rd September 2015 when Edison published a note proclaiming "valuation - considerable upside" and flagging triggers for a re-rating. Hmmm... so that is a fall of c90% in the seven months since that buy note - is that the worst research note of the past 12 months?


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

ARB

Worthless Argo what news Helios?

Sunday »

Bearcast

Tom Winnifrith Bearcast: macrobabble calls

 

AAU

Gold up Ariana down

Saturday »

AVCT

Cassava, A warning to Avacta Sharehoders 

Friday »

ALU

Alumasc Group – a growth Buy

 

VCP

Victoria - The roll up unravels

 

HEMO

Hemogenyx is a short – target 0p

 

ECR

ECR, the timing is unfortunate

 

APH

Alliance Pharma – a recovery Buy?

 

PICH

Pitch Pit – this stinks

 

GEX

Georgina Energy: Lyin’ Yet again

Time left: 05:43:24